Article
TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Nature communications - 4 Oct 2023
Heyes Elizabeth, Wilhelmson Anna S, Wenzel Anne, Manhart Gabriele, Eder Thomas, Schuster Mikkel B, Rzepa Edwin, Pundhir Sachin, D'Altri Teresa, Frank Anne-Katrine, Gentil Coline, Woessmann Jakob, Schoof Erwin M, Meggendorfer Manja, Schwaller Jürg, Haferlach Torsten, Grebien Florian, Porse Bo T
Abstract excerpt
The myeloid transcription factor CEBPA is recurrently biallelically mutated (i.e., double mutated; CEBPADM) in acute myeloid leukemia (AML) with a combination of hypermorphic N-terminal mutations (CEBPANT), promoting expression of the leukemia-associated p30 isoform, and amorphic C-terminal mutations. The most frequently co-mutated genes in CEBPADM AML are GATA2 and TET2, however the molecular mechanisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.